<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="299">
  <stage>Registered</stage>
  <submitdate>26/08/2005</submitdate>
  <approvaldate>26/08/2005</approvaldate>
  <actrnumber>ACTRN12605000237684</actrnumber>
  <trial_identification>
    <studytitle>Phase II Study of AVAC (TM) for the Treatment of  Atopic Dermatitis in Children</studytitle>
    <scientifictitle>A blinded, randomised, placebo-controlled Phase II study to evaluate the safety and efficacy of 12.5 mcg AVAC (TM) (delipidated, deglycolipidated and arabinogalactan depleted derivative of heat-killed Mycobacterium vaccae suspension) in children with moderate-to-severe atopic dermatitis (AD)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Childhood eczema</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>3 intradermal injections of AVAC (TM) at intervals of 2 weeks (Weeks 0, 2 and 4)</interventions>
    <comparator>Placebo (saline) </comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change relative to baseline in six-area, six-sign, atopic dermatitis (SASSAD) score at 3 months.</outcome>
      <timepoint>Measured at baseline, 2 and 4 weeks, and 2, 3 and 6 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>EFFICACY: Change relative to baseline in SASSAD score</outcome>
      <timepoint>At 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>% AD-affected body surface area</outcome>
      <timepoint>3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QoL </outcome>
      <timepoint>3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pruritus</outcome>
      <timepoint>Weeks 2, 4 and at 2, 3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep disturbance</outcome>
      <timepoint>Weeks 2,4 and at 2, 3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Topical corticosteroid use</outcome>
      <timepoint>Weeks 2, 4 and at 2, 3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total serum IgE</outcome>
      <timepoint>3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SAFETY: Vital signs, adverse events</outcome>
      <timepoint>All visits</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical examination, pregnancy test</outcome>
      <timepoint>Baseline, final visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard laboratory safety parameters</outcome>
      <timepoint>Baseline, 3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Injection site reactions</outcome>
      <timepoint>Weeks 2, 4 and at 2, 3 and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of moderate-to-severe atopic dermatitis (AD). Severity defined according to Rajka and Langeland criteria; atopic dermatitis defined according to UK Atopic Dermatitis Working Party criteria.</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes</concealment>
    <sequence>Computer-generated block randomisation scheme</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>7/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genesis Research &amp; Development Corporation Ltd</primarysponsorname>
    <primarysponsoraddress>1 Fox St Parnell Auckland 1001</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Genesis Reserach &amp; development Corporation Ltd</fundingname>
      <fundingaddress>1 Fox St Parnell Auckland 1001</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Ethics Committee Y</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Diana Gash</name>
      <address>Genesis Research &amp; Development Corporation Ltd
1 Fox Street
Parnell Auckland 1001</address>
      <phone>+64 9 3735600</phone>
      <fax>+64 9 3732189</fax>
      <email>d.gash@genesis.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Diana Gash</name>
      <address>Genesis Research &amp; Development Corporation Ltd
1 Fox Street
Parnell Auckland 1001</address>
      <phone>+64 9 3735600</phone>
      <fax>+64 9 3732189</fax>
      <email>d.gash@genesis.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Diana Gash</name>
      <address>Genesis Research &amp; Development Corporation Ltd 1 Fox St Parnell Auckland 1001</address>
      <phone>+64 9 3735600</phone>
      <fax>+64 9 3732189</fax>
      <email>d.gash@genesis.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>